Our vision: Bring individualized treatment decisions to all patients diagnosed with skin cancer

NeraCare is a leading developer of laboratory tests for personalized survival prediction of melanoma patients. 

Our tests provide actionable, tumor-specific information for each individual patient. The information is used to improve patient care, most importantly to guide adjuvant therapy decision-making.

Through its partnerships with pharmaceutical companies and world leading investigators, NeraCare is at the forefront of designing cutting-edge clinical trials to help expand access to drugs for early stage patients.
NeraCare's first development is a quantitative RT-PCR-based assay – MELAGENIX to help make individualised therapeutic decisions for stage II/III melanoma patients. 

NeraCare's second development is an immunohistochemistry-based test – immunoprint – with focus on changing the treatment algorithm for patients diagnosed with early stage melanoma.

Further products for non-melanoma skin cancers are currently under development.

Founders / Management

Friedrich Ackermann

Co-Founder & Board Member


Friedrich previously worked as a management consultant (McKinsey & Company) and investment banker (Morgan Stanley). He holds an MSc in Management from the London School of Economics and an MPH in Epidemiology from Yale University.

Button

Daniel von Janowski

Co-Founder & Chief Executive Officer


Daniel previously worked as M&A investment banker (Evercore) and management consultant (Roland Berger). He holds an MSc in Management from the London School of Economics and a BSc in Engineering from TU Darmstadt. 

Button

Dr. Michael Oed

Chief Development Officer


Michael is a seasoned professional  in IVD Development, QM & Regulatory Affaris. Prior to joining NeraCare, he served as Vice President Development/QMR at BioNTech and build BioNTech Diagnostics from scratch. He holds a PhD in Biology.

Button

Younes Salahdine

Chief Operating Officer


With experience in M&A investment banking and operations at Deutsche Bank and multiple startups, Younes helped build the international offices (AUS/USA) at NeraCare. He studied Computer Science & Management at TU Darmstadt and Finance at WHU.

Button

Dr. Matthias Ackermann

Founding Investor & Managing Director


Matthias is a founding investor into NeraCare. He is a seasoned entrepreneur, investor and veteran of the oncology industry (ex-Amgen; previous exit to Alliance Boots / KKR).

Button

Board

Dr. Matthias Kromayer

General Partner @ MIG AG


A biologist by training, Matthias has over 20 years of experience in healthcare and pharmaceutical strategy and investments. He has been part of MIG Verwaltungs AG since 2010.

Button

Dr. Peter Graf

Investment Manager @ BayBG


A molecular biologist by training, Peter worked as a Research Scientist at Max Planck Institute. He has been a life science investor with BayBG since 2018, focusing on digital health, deep tech, diagnostics and biotech ventures.

Button

Friedrich Ackermann

Co-Founder @ NeraCare


Friedrich previously worked as a management consultant (McKinsey & Company) and investment banker (Morgan Stanley). He holds an MSc in Management from the London School of Economics and an MPH in Epidemiology from Yale University.

Button

Dr. Helge Lubenow

CEO @ Proteomedix AG


Helge is CEO of Proteomedix AG which develops biomarker signatures for prostate cancer diagnostics. She previously spent 18 years at Qiagen in R&D and commercial roles and serves on the boards of epigenomics, tesa labtec and evorion biotechnologies.

Button
Share by: